Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.45 |
| ▸ | TACR1 | P25103 | 4/20 | 0.45 |
| ▸ | TACR3 | P29371 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 11/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025558 | 1.00 | TACR2 (0.45) | TACR2TACR1TACR3ALDH1A1S1PR1 | |
| SCHEMBL14484758 | 0.94 | TACR2 (0.39) | TACR2TACR1TACR3S1PR1S1PR3 | |
| SCHEMBL14485552 | 0.93 | TACR2 (0.38) | TACR2TACR1TACR3ALDH1A1P2RX7 | |
| SCHEMBL6603926 | 0.91 | TACR2 (0.39) | TACR2TACR1TACR3PTGFR | |
| SCHEMBL14485288 | 0.91 | TACR2 (0.38) | TACR2TACR1TACR3S1PR1S1PR3 | |
| SCHEMBL6605525 | 0.91 | TACR2 (0.37) | TACR2TACR1TACR3P2RX7PTGFR | |
| SCHEMBL14144503 | 0.90 | TACR2 (0.41) | TACR2TACR1TACR3S1PR1S1PR3 | |
| SCHEMBL14484786 | 0.90 | TACR2 (0.37) | TACR2TACR1TACR3S1PR1S1PR3 | |
| SCHEMBL14485492 | 0.89 | TACR2 (0.36) | TACR2TACR1TACR3S1PR1S1PR3 | |
| SCHEMBL14484775 | 0.88 | TACR2 (0.36) | TACR2TACR1TACR3S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345899-B1 | N-substituted amides as NK1 receptor antagonists | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-7064136-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| US-20040058916-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058916-A1 | Compounds | CYP11B2, CYP11B1, PCSK9 | TACR2 2202/4885TACR1 1821/4885TACR3 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.